COVID-19 vaccine safety surveillance Our work Main navigation National vaccine safety surveillance Active vaccine safety surveillance COVID-19 vaccine safety surveillance What is AusVaxSafety doing? How will AusVaxSafety monitor vaccine safety? Information for immunisation providers COVID-19 vaccine safety surveillance FAQ COVID-19 vaccine safety data Adverse event of special interest (AESI) long-term follow-up program Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN) Vaccine safety in Australia AusVaxSafety summary report Publications AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia. This is to ensure ongoing safety of COVID-19 vaccines used in Australia to promote provider and public confidence in the vaccination program. Click on the tiles below to find out more. What is AusVaxSafety doing? AusVaxSafety is conducting active safety surveillance of COVID-19 vaccines in Australia. Find out more here. How does AusVaxSafety monitor vaccine safety? Find out how is AusVaxSafety monitoring COVID-19 vaccine safety here. Information for immunisation providers GPs/immunisation providers can get involved in monitoring COVID-19 vaccine safety. Find out more here. COVID-19 vaccine safety surveillance FAQ Answers to some of the frequently asked questions about COVID-19 vaccine safety surveillance in Australia. COVID-19 vaccine safety data COVID-19 vaccine safety results are available publicly. Find out more here. Our work Main navigation National vaccine safety surveillance Active vaccine safety surveillance COVID-19 vaccine safety surveillance What is AusVaxSafety doing? How will AusVaxSafety monitor vaccine safety? Information for immunisation providers COVID-19 vaccine safety surveillance FAQ COVID-19 vaccine safety data Adverse event of special interest (AESI) long-term follow-up program Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN) Vaccine safety in Australia AusVaxSafety summary report Publications News & events All news & events 14 September 2023 | News Vaxtracker wins Hunter New England Health Excellence Award 17 May 2023 | News Subcutaneous and intradermal administration of mpox vaccine well tolerated, AusVaxSafety study finds 10 May 2023 | News New bivalent BA.4/BA.5 COVID-19 booster vaccines well tolerated by Australians, new AusVaxSafety data show 20 April 2023 | News Influenza is back in Australia in 2023: Why a flu shot is so important, who is eligible and what to expect in the days following your vaccination